New Clinical Evidence on Emicizumab and Breastfeeding – JTH
Journal of Thrombosis and Haemostasis shared a post on LinkedIn about a recent article by Simon Alexander Krooss et al., adding:
“Transfer of emicizumab into breast milk in postpartum acquired hemophilia A
Acquired hemophilia A can arise postpartum, and emicizumab is increasingly used for prophylaxis, yet whether it passes into breast milk was unknown.
In a woman who developed AHA four months after delivery, emicizumab reached up to 20 μg/mL in breast milk against a steady-state plasma level of 42 μg/mL.
Anti-FVIII antibodies appeared in plasma but not milk.”
Title: Transfer of emicizumab into breast milk in postpartum acquired hemophilia A
Authors: Simon Alexander Krooss, Tim Halling, Dirk Varnholt, Annika Klingberg, Korbinian Brand, Sonja Werwitzke, Heiner Wedemeyer, Christiane Dobbelstein, Andreas Tiede, Olga Oleshko
Other posts about Journal of Thrombosis and Haemostasis on Hemostasis Today.
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide
-
Sep 3, 2026, 17:48Isabel Sá: Starting a New Chapter as a Clinical Scientist in Molecular Genetics and Haematology
-
Sep 3, 2026, 17:40Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB
-
Sep 3, 2026, 17:24N. Mariana S. Vasquez: JAK2 Mutations The High-Yield Map of Myeloproliferative Neoplasms
-
Sep 3, 2026, 17:08Khusi Dhara: Why Women Need to Pay Attention to Iron
-
Sep 3, 2026, 16:54Ralf Ludwig։ Testing Human-Targeted Therapies in a Human Immune System
-
Sep 3, 2026, 16:35Mohsen Salimi: Non-Contrast Chest CT as a Biomarker for Mild-to-Moderate Anemia
-
Sep 3, 2026, 16:10Tanzeel Alamin Almahdi Gorashi: NLR as an Accessible Biomarker for Monitoring Pediatric Sickle Cell Anemia